Regeneroncourage Regeneron Pharmaceuticals is actively engaged in the development and research of peptide-based therapeutics, exploring their potential across a spectrum of diseases作者：GY Liu·2023·被引用次数：2—We report the discovery of a novel covalent cross-link formed via an imine bond between lysine and serine residues.. This focus on peptides is evident in their investigational medicines pipeline, encompassing areas like obesity, cancer, and severe infectionsDiscovery and Characterization of an Acid-Labile Serine .... Significant developments include licensing agreements for novel peptide therapies, such as Hansoh's HS-20094, and ongoing clinical trials for peptide-focused drug candidates like REGN7544This study is researching an experimental drug calledREGN7544(called study drug). The study is focused on participants with POTS..
Regeneron's commitment to peptide research is highlighted by its diversified pipelineResults showed that each computationally generated ligand had binding affinity values consistently surpassing the accepted value of the natural ligand's binding .... One notable area of exploration is obesity, where the company is investigating approaches aimed at promoting muscle preservation during weight loss. This includes the development of myostatin and activin A inhibitors, such as trevogrumab, which has shown promise in combination with semaglutide to enhance fat loss while maintaining lean mass. The COURAGE trial is a key study in this area, providing valuable Phase II data on these combination therapies.
Beyond obesity, Regeneron is also leveraging peptide research for other therapeutic targets. The investigational drug REGN7544 is being studied for conditions such as sepsis-induced hypotension and POTS (Postural Orthostatic Tachycardia Syndrome)JB: Speaker: Galderma, Krystal, Sanofi, Pfizer,Regeneron, and Verrica; Consultant: Dermavant; Investigator: AbbVie, Amgen, Arcutis, Dermata, Dermavant, Eli .... This reflects a broader strategy to utilize peptide-based mechanisms to address critical unmet medical needs.
Regeneron's scientific endeavors extend to advanced peptide research, including the optimization of analytical techniques. Scientists at the company have developed methods for simple endoglycosidase-assisted peptide mapping, crucial for characterizing complex biomolecules. Furthermore, research is underway to optimize sample digestion for antibody-drug conjugates (ADCs), with a particular focus on improving the recovery of hydrophobic peptides, which can be challenging to analyze. This sophisticated approach to peptide science underpins their drug discovery and development efforts.
Collaborations and licensing agreements play a vital role in Regeneron's peptide strategy. The company has entered into significant in-licensing agreements, such as the one with Hansoh Pharmaceuticals for HS-20094, a therapy that could bolster Regeneron's portfolio in areas like obesity.作者：GY Liu·2023·被引用次数：2—We report the discovery of a novel covalent cross-link formed via an imine bond between lysine and serine residues. These partnerships allow Regeneron to access promising external innovations and accelerate the development of novel peptide-based treatments. Such strategic moves underscore the growing importance of peptides in the pharmaceutical landscape and Regeneron's proactive stance in harnessing their therapeutic potentialTyler Greer's research works | Regeneron and other places.
Regeneron's exploration of peptides is not limited to specific disease areas but also extends to fundamental research and the development of advanced therapeutic modalitiesREGN7544 / Regeneron. The company is investigating bispecific antibodies with potential applications in cancer therapy, hinting at the integration of peptide-related insights into broader immunotherapeutic strategies. Moreover, their internal manufacturing capabilities for a range of biopharmaceuticals, including those involving peptides, demonstrate a comprehensive approach to bringing these complex molecules from the lab to patients. This multifaceted engagement with peptide science positions Regeneron at the forefront of therapeutic innovation2025年10月29日—Explore Regeneron's pipeline of investigational medicinesadvancing through clinical trials for a range of serious diseases..
Join the newsletter to receive news, updates, new products and freebies in your inbox.